SyntekaBio, Inc. operates as a genomic big data and artificial intelligence drug discovery company. It creates new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology, such as biomarkers for individual cancer drug screening and disease susceptibility by immunotyping, pharmacogenomic typing, and predicting multi-omics information-based drug adverse effects, etc. The company also developing new antigen prediction technology that can be used together with therapeutic vaccines and cell therapy products, and prediction of antibody therapeutics. SyntekaBio, Inc. was founded in 2009 and is headquartered in Daejeon, South Korea.
Stock data | 2024 | Change |
---|---|---|
Employees | 52.00 | N/A |